Completion of Allen Brain Atlas Hailed as “Epoch-Making”

Sept. 27, 2006 | Microsoft co-founder and philanthropist Paul G. Allen, founder of the Allen Institute for Brain Science (AIBS), announced the completion of the Allen Brain Atlas at a press conference in Washington, D.C., on Tuesday.

The Allen Brain Atlas is a Web-based, graphic 3-D database of the mouse brain that shows the location of expression sites of more than 21,000 genes at the cellular level. Because humans and mice share more than 90 percent of their genes, the completion of this database has important implications for research into neurological disorders that affect humans.

Francis Collins, director of the National Human Genome Research Institute, was among those attending the event. Also present were Sen. Ted Stevens of Alaska and Sen. Patty Murray of Washington, both of whom were described as strong supporters of legislation for research and healthcare funding. Murray expressed the hope that the Atlas would be a catalyst for the understanding, diagnosis, and treatment of, among other conditions, traumatic brain injuries sustained by soldiers in combat.

In making the announcement, Allen said it was his fascination with the human brain that led to his funding this project. Coming from a software programming background, Allen said, “the more you learn about computers, the more you wonder how the human brain functions and solves problems like vision and speech understanding, in ways that no computer can do today.”

Indeed, Allen has been described by Mark Boguski, founding director of the AIBS before moving to Novartis, as “a technologist and visionary who has always been interested in science and its applications.” (See Synapses in Seattle, Bio-IT World, Nov. 2003.)

Allen recalled assembling a group of experts, including top neuroscientists and geneticists, a few years ago and asking them what could be done that was not already being done to accelerate the field of neuroscience.  The answer to that question led to the launch, in 2003, with $100 million in seed money from Allen, of the Allen Brain Atlas. “I try to find projects like this and apply resources to problems that will have an impact worldwide,” said Allen. “This database is online. Scientists from anywhere in the world can get online and within minutes be looking at genes of interest. We’ve seen fine structures in the mouse brain that have never been seen before.”

AIBS chief scientific officer Allan Jones added that the Atlas was created by a multidisciplinary team of about 80 people -- Ph.Ds in math and physics, neuroscientists, software engineers, and even an aeronautics engineer -- working with “factory-like efficiency” on one mission.

The Atlas shows where each gene is expressed in a series of thin tissue sections spaced evenly throughout the brain. The completed database includes an enormous amount of data: the equivalent of 85 million photos, or 600 terabytes, or a quarter million microscope slides, said Jones. The powerful computational tools developed by the team are available to all researchers at no cost through an easy-to-use interface.

Despite the daunting scale of the project, chief operating officer Elaine Jones (no relation) noted proudly that the Atlas was completed on time and about 20 percent under budget.

The Gift of Time
Even before the formal launch of the Atlas, about 250 scientists from academia, biotechs, and the pharmaceutical industry were visiting it daily. Allan Jones finds that rewarding. “The nice thing about my job is I get to travel and talk to people who tell me how [the Atlas] has helped their project,” he said. In a recent conversation, a scientist told him he was able to corroborate a hypothesis with a few mouse clicks using the Atlas—work that would have previously taken a lab technician a long time to corroborate. “We’ve done the experiment for them, so they can spend time furthering their research,” said Jones. “We’ve given them the gift of time.”

David Anderson, professor of biology at the California Institute of Technology and a member of the AIBS scientific advisory board, and also one of the scientists invited to Paul Allen’s original meeting, said the Atlas had exceeded his wildest dreams.

To illustrate its significance, he asked listeners to imagine they were traveling on the space shuttle looking down on Earth, and that they had X-ray vision and could see beneath the surface. “You would be able to see where deposits of gold, silver, platinum, and oil are. You would not have to do any prospecting, but could go straight to mining.” That’s what the Brain Atlas does for scientists, he said. Before, Ph.D. students spent years prospecting. Now they can begin their work by mining the data. 

Anderson compared the Allen Brain Atlas in scope and impact to the Human Genome Project. “It’s an epoch-making discovery for neuroscience because genes implicated in a disease [such as epilepsy or Alzheimer’s] can immediately be pinpointed in the brain.” Conversely, he said, scientists can use the Atlas to narrow down the “field of suspects” for a gene by looking at the “neighborhoods” of the brain where they function.

Next Stop: Neocortex
Looking ahead to the next stage in the AIBS’s development, Allan Jones pointed out that human brain disease affects everyone, either firsthand or through a relative suffering from Alzheimer’s, for example. He noted that with one quadrillion communication points, the human brain is an enormously complex organ, but that “you can use a reductionist approach to understand” its workings.

And it is the human brain – the neocortex in particular – that will be the focus of the next stage of the AIBS’s work. Anderson cited three specific goals:

  • Mine the data and create better tools
  • Collaborate with other institutions
  • Explore the human neocortex – the part that makes us uniquely human, and which constitutes 80 percent of our brain.

As a neuroscientist, Anderson looks forward to a database of the human brain that could show changes produced by conditions such as chronic stress or pain, drug addiction, and even learning disabilities.

Diseases such as Alzheimer’s and Parkinson’s, or epilepsy and autism, may also benefit from a 3-D database of the human brain. “It’s up to us to mine this rich resource and discover the intellectual riches,” said Anderson.

The AIBS will also seek collaborations and funding partnerships as it moves ahead.

------------------------------------------

Subscribe to Bio-IT World  magazine.

 



White Papers & Special Reports

sgi whp 2
Managing the Modern Genomics Data Flood
Sponsored by SGI

Managing and storing the perfect storm of multi-disciplined data pouring from next generation sequencers and other omics instruments is a central challenge in life sciences. Discover in this paper how the SGI ArcFiniti storage solution, optimized for unstructured genomics and life sciences data can: 

  • Reduce costs, proactively protect data integrity, and deliver the high performance I/O required for genomics data processing and analysis.  
  • Effectively manage capacities from 156TB to 1.4PB as a disk based, integrated hardware and software platform 


sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .